Loading...
Header Logo
Institute for Clinical and Translational Research

Profiles



Video Tutorials
Keywords
Last Name
Institution

YU SHEN

TitleProfessor
InstitutionMD Anderson
DepartmentBiostatistics
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Swanson AJ, Castel LD, McKenna PA, Shen YA, Sagar B. Integration of the National Comprehensive Cancer Network (NCCN) Distress Screening Tool as a Guidepost for Telephonic Oncology Case Management. Prof Case Manag. 2019 May/Jun; 24(3):148-154. PMID: 30946253.
      View in: PubMed
    2. Shen Y, Fujii T, Ueno NT, Tripathy D, Fu N, Zhou H, Ning J, Xiao L. Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis. Breast Cancer Res Treat. 2019 Jan; 173(1):1-9. PMID: 30242579.
      View in: PubMed
    3. Shen Y, Ning J, Qin J. Nonparametric and semiparametric regression estimation for length-biased survival data. Lifetime Data Anal. 2017 01; 23(1):3-24. PMID: 27086362.
      View in: PubMed
    4. Fujii T, Le Du F, Xiao L, Kogawa T, Barcenas CH, Alvarez RH, Valero V, Shen Y, Ueno NT. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis. JAMA Oncol. 2015 Dec; 1(9):1311-8. PMID: 26402167.
      View in: PubMed
    5. Lautner M, Lin H, Shen Y, Parker C, Kuerer H, Shaitelman S, Babiera G, Bedrosian I. Disparities in the Use of Breast-Conserving Therapy Among Patients With Early-Stage Breast Cancer. JAMA Surg. 2015 Aug; 150(8):778-86. PMID: 26083835.
      View in: PubMed
    6. Hoffman KE, Niu J, Shen Y, Jiang J, Davis JW, Kim J, Kuban DA, Perkins GH, Shah JB, Smith GL, Volk RJ, Buchholz TA, Giordano SH, Smith BD. Physician variation in management of low-risk prostate cancer: a population-based cohort study. JAMA Intern Med. 2014 Sep; 174(9):1450-9. PMID: 25023650.
      View in: PubMed
    7. Ahern CH, Shih YC, Dong W, Parmigiani G, Shen Y. Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk. Br J Cancer. 2014 Oct 14; 111(8):1542-51. PMID: 25137022.
      View in: PubMed
    8. Eberth JM, Xu Y, Smith GL, Shen Y, Jiang J, Buchholz TA, Hunt KK, Black DM, Giordano SH, Whitman GJ, Yang W, Shen C, Elting L, Smith BD. Surgeon influence on use of needle biopsy in patients with breast cancer: a national medicare study. J Clin Oncol. 2014 Jul 20; 32(21):2206-16. PMID: 24912900.
      View in: PubMed
    9. Rueth NM, Lin HY, Bedrosian I, Shaitelman SF, Ueno NT, Shen Y, Babiera G. Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database. J Clin Oncol. 2014 Jul 01; 32(19):2018-24. PMID: 24888808.
      View in: PubMed
    10. Deshmukh AA, Cantor SB, Crosby MA, Dong W, Shen Y, Bedrosian I, Peterson SK, Parker PA, Brewster AM. Cost of contralateral prophylactic mastectomy. Ann Surg Oncol. 2014 Sep; 21(9):2823-30. PMID: 24809301.
      View in: PubMed
    11. Middleton LP, Sneige N, Coyne R, Shen Y, Dong W, Dempsey P, Bevers TB. Most lobular carcinoma in situ and atypical lobular hyperplasia diagnosed on core needle biopsy can be managed clinically with radiologic follow-up in a multidisciplinary setting. Cancer Med. 2014 Jun; 3(3):492-9. PMID: 24639339.
      View in: PubMed
    12. Shih YC, Xu Y, Dong W, Smieliauskas F, Giordano S, Shen Y. First do no harm: population-based study shows non-evidence-based trastuzumab prescription may harm elderly women with breast cancer. Breast Cancer Res Treat. 2014 Apr; 144(2):417-25. PMID: 24557339.
      View in: PubMed
    13. Wood DP. Re: A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. J Urol. 2013 Dec; 190(6):2019. PMID: 24209516.
      View in: PubMed
    14. Brewer TM, Masuda H, Liu DD, Shen Y, Liu P, Iwamoto T, Kai K, Barnett CM, Woodward WA, Reuben JM, Yang P, Hortobagyi GN, Ueno NT. Statin use in primary inflammatory breast cancer: a cohort study. Br J Cancer. 2013 Jul 23; 109(2):318-24. PMID: 23820253.
      View in: PubMed
    15. Ning J, Qin J, Asgharian M, Shen Y. Empirical likelihood-based confidence intervals for length-biased data. Stat Med. 2013 Jun 15; 32(13):2278-91. PMID: 23027662.
      View in: PubMed
    16. Siefker-Radtke AO, Dinney CP, Shen Y, Williams DL, Kamat AM, Grossman HB, Millikan RE. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. Cancer. 2013 Feb 01; 119(3):540-7. PMID: 22914978.
      View in: PubMed
    17. Liu H, Qin J, Shen Y. Imputation for semiparametric transformation models with biased-sampling data. Lifetime Data Anal. 2012 Oct; 18(4):470-503. PMID: 22903245.
      View in: PubMed
    18. Albert JM, Liu DD, Shen Y, Pan IW, Shih YC, Hoffman KE, Buchholz TA, Giordano SH, Smith BD. Nomogram to predict the benefit of radiation for older patients with breast cancer treated with conservative surgery. J Clin Oncol. 2012 Aug 10; 30(23):2837-43. PMID: 22734034.
      View in: PubMed
    19. Brewster AM, Bedrosian I, Parker PA, Dong W, Peterson SK, Cantor SB, Crosby M, Shen Y. Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status. Cancer. 2012 Nov 15; 118(22):5637-43. PMID: 22517269.
      View in: PubMed
    20. Lynch SP, Shen Y, Kamat A, Grossman HB, Shah JB, Millikan RE, Dinney CP, Siefker-Radtke A. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol. 2013 Aug; 64(2):307-13. PMID: 22564397.
      View in: PubMed
    21. Shen Y, Ning J, Qin J. Likelihood approaches for the invariant density ratio model with biased-sampling data. Biometrika. 2012 Jun; 99(2):363-378. PMID: 23843663.
      View in: PubMed
    22. Choi W, Shah JB, Tran M, Svatek R, Marquis L, Lee IL, Yu D, Adam L, Wen S, Shen Y, Dinney C, McConkey DJ, Siefker-Radtke A. p63 expression defines a lethal subset of muscle-invasive bladder cancers. PLoS One. 2012; 7(1):e30206. PMID: 22253920.
      View in: PubMed
    23. Rogers D, Boyd DD, Fox EE, Cooper S, Goldhagen M, Shen Y, Del Junco DJ. Prostate cancer incidence in U.S. Air Force aviators compared with non-aviators. Aviat Space Environ Med. 2011 Nov; 82(11):1067-70. PMID: 22097644.
      View in: PubMed
    24. Tsai TF, Ho JC, Song M, Szapary P, Guzzo C, Shen YK, Li S, Kim KJ, Kim TY, Choi JH, Youn JI. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci. 2011 Sep; 63(3):154-63. PMID: 21741220.
      View in: PubMed
    25. Ning J, Qin J, Shen Y. Buckley-James-type estimator with right-censored and length-biased data. Biometrics. 2011 Dec; 67(4):1369-78. PMID: 21385160.
      View in: PubMed
    26. Stenzl A, Burger M, Fradet Y, Mynderse LA, Soloway MS, Witjes JA, Kriegmair M, Karl A, Shen Y, Grossman HB. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol. 2010 Nov; 184(5):1907-13. PMID: 20850152.
      View in: PubMed
    27. Shen Y, Ning J, Qin J. Analyzing Length-biased Data with Semiparametric Transformation and Accelerated Failure Time Models. J Am Stat Assoc. 2009 09 01; 104(487):1192-1202. PMID: 21057599.
      View in: PubMed
    28. Qin J, Shen Y. Statistical methods for analyzing right-censored length-biased data under cox model. Biometrics. 2010 Jun; 66(2):382-92. PMID: 19522872.
      View in: PubMed
    29. Shen Y, Dong W, Feig BW, Ravdin P, Theriault RL, Giordano SH. Patterns of treatment for early stage breast cancers at the M. D. Anderson Cancer Center from 1997 to 2004. Cancer. 2009 May 15; 115(10):2041-51. PMID: 19288569.
      View in: PubMed
    30. Ahern CH, Shen Y. Cost-effectiveness analysis of mammography and clinical breast examination strategies: a comparison with current guidelines. Cancer Epidemiol Biomarkers Prev. 2009 Mar; 18(3):718-25. PMID: 19258473.
      View in: PubMed
    31. Margulis V, Matin SF, Tannir N, Tamboli P, Shen Y, Lozano M, Swanson DA, Jonasch E, Wood CG. Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. Urology. 2009 Feb; 73(2):337-41. PMID: 18950837.
      View in: PubMed
    32. Shen Y, Costantino JP, Qin J. Tamoxifen chemoprevention treatment and time to first diagnosis of estrogen receptor-negative breast cancer. J Natl Cancer Inst. 2008 Oct 15; 100(20):1448-53. PMID: 18840821.
      View in: PubMed
    33. Davis JW, Chang DW, Chevray P, Wang R, Shen Y, Wen S, Pettaway CA, Pisters LL, Swanson DA, Madsen LT, Huber N, Troncoso P, Babaian RJ, Wood CG. Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer. Eur Urol. 2009 May; 55(5):1135-43. PMID: 18783876.
      View in: PubMed
    34. Harris LD, De La Cerda J, Tuziak T, Rosen D, Xiao L, Shen Y, Sabichi AL, Czerniak B, Grossman HB. Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray. Mol Carcinog. 2008 Sep; 47(9):678-85. PMID: 18288642.
      View in: PubMed
    35. Dong W, Berry DA, Bevers TB, Kau SW, Hsu L, Theriault RL, Shen Y. Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experience. Cancer Epidemiol Biomarkers Prev. 2008 May; 17(5):1096-103. PMID: 18483331.
      View in: PubMed
    36. Bekele BN, Ji Y, Shen Y, Thall PF. Monitoring late-onset toxicities in phase I trials using predicted risks. Biostatistics. 2008 Jul; 9(3):442-57. PMID: 18084008.
      View in: PubMed
    37. Cong XJ, Yin G, Shen Y. Marginal analysis of correlated failure time data with informative cluster sizes. Biometrics. 2007 Sep; 63(3):663-72. PMID: 17825000.
      View in: PubMed
    38. Beran M, Wen S, Shen Y, Onida F, Jelinek J, Cortes J, Giles F, Kantarjian H. Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System. Leuk Lymphoma. 2007 Jun; 48(6):1150-60. PMID: 17577778.
      View in: PubMed
    39. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, Bajorin DF, Reuter VE, Herr H, Old LJ, Sato E. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A. 2007 Mar 06; 104(10):3967-72. PMID: 17360461.
      View in: PubMed
    40. Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, Huan S, Huang M, Liu J, Sahin AA, Hunt KK, Bast RC, Shen Y, Issa JP, Yu Y. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res. 2007; 9(4):R57. PMID: 17764565.
      View in: PubMed
    41. Shen Y, Dong W, Esteva FJ, Kau SW, Theriault RL, Bevers TB. Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M.D. Anderson Cancer Center? Breast Cancer Res Treat. 2007 May; 102(3):347-56. PMID: 17028980.
      View in: PubMed
    42. Sharma P, Shen Y, Wen S, Bajorin DF, Reuter VE, Old LJ, Jungbluth AA. Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res. 2006 Sep 15; 12(18):5442-7. PMID: 17000678.
      View in: PubMed
    43. Shen Y, Cheng Y. Adaptive design: estimation and inference with censored data in a semiparametric model. Biostatistics. 2007 Apr; 8(2):306-22. PMID: 16787996.
      View in: PubMed
    44. Beran M, Shen Y, Onida F, Wen S, Kantarjian H, Estey E. Prognostic significance of monocytosis in patients with myeloproliferative disorders. Leuk Lymphoma. 2006 Mar; 47(3):417-23. PMID: 16396764.
      View in: PubMed
    45. Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, Shen Y. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA. 2006 Jan 18; 295(3):299-305. PMID: 16418465.
      View in: PubMed
    46. Berry DA, Inoue L, Shen Y, Venier J, Cohen D, Bondy M, Theriault R, Munsell MF. Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. J Natl Cancer Inst Monogr. 2006; (36):30-6. PMID: 17032892.
      View in: PubMed
    47. Paci E, Ponti A, Crocetti E, Zappa M, Segnan N. Re: Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst. 2005 Dec 21; 97(24):1853-4; author reply 1854. PMID: 16368949.
      View in: PubMed
    48. Shen Y, Huang X. Nonparametric estimation of asymptomatic duration from a randomized prospective cancer screening trial. Biometrics. 2005 Dec; 61(4):992-9. PMID: 16401272.
      View in: PubMed
    49. Cong XJ, Shen Y, Miller AB. Estimation of age-specific sensitivity and sojourn time in breast cancer screening studies. Stat Med. 2005 Oct 30; 24(20):3123-38. PMID: 15977269.
      View in: PubMed
    50. Kamat AM, Jacobsohn KM, Troncoso P, Shen Y, Wen S, Babaian RJ. Validation of criteria used to predict extraprostatic cancer extension: a tool for use in selecting patients for nerve sparing radical prostatectomy. J Urol. 2005 Oct; 174(4 Pt 1):1262-5. PMID: 16145389.
      View in: PubMed
    51. Amin HM, Yang Y, Shen Y, Estey EH, Giles FJ, Pierce SA, Kantarjian HM, O'Brien SM, Jilani I, Albitar M. Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias. Leukemia. 2005 Sep; 19(9):1567-72. PMID: 16049515.
      View in: PubMed
    52. Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst. 2005 Aug 17; 97(16):1195-203. PMID: 16106024.
      View in: PubMed
    53. Bekele BN, Shen Y. A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial. Biometrics. 2005 Jun; 61(2):343-54. PMID: 16011680.
      View in: PubMed
    54. Yin G, Shen Y. Adaptive design and estimation in randomized clinical trials with correlated observations. Biometrics. 2005 Jun; 61(2):362-9. PMID: 16011682.
      View in: PubMed
    55. Leibovici D, Lee AK, Cheung RM, Spiess PE, Kuban DA, Rosser CJ, Shen Y, Yang Y, Chichakli R, Pisters LL. Symptomatic local recurrence of prostate carcinoma after radiation therapy. Cancer. 2005 May 15; 103(10):2060-6. PMID: 15822114.
      View in: PubMed
    56. Shen Y, Zelen M. Robust modeling in screening studies: estimation of sensitivity and preclinical sojourn time distribution. Biostatistics. 2005 Oct; 6(4):604-14. PMID: 15860542.
      View in: PubMed
    57. Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, Shen Y. Detection of bladder cancer using a point-of-care proteomic assay. JAMA. 2005 Feb 16; 293(7):810-6. PMID: 15713770.
      View in: PubMed
    58. Shen Y, Parmigiani G. A model-based comparison of breast cancer screening strategies: mammograms and clinical breast examinations. Cancer Epidemiol Biomarkers Prev. 2005 Feb; 14(2):529-32. PMID: 15734983.
      View in: PubMed
    59. Davis DW, Takamori R, Raut CP, Xiong HQ, Herbst RS, Stadler WM, Heymach JV, Demetri GD, Rashid A, Shen Y, Wen S, Abbruzzese JL, McConkey DJ. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):678-89. PMID: 15701856.
      View in: PubMed
    60. Yin G, Shen Y. Self-designing trial combined with classical group sequential monitoring. J Biopharm Stat. 2005; 15(4):667-75. PMID: 16022171.
      View in: PubMed
    61. Cheng Y, Shen Y. Estimation of a parameter and its exact confidence interval following sequential sample size reestimation trials. Biometrics. 2004 Dec; 60(4):910-8. PMID: 15606411.
      View in: PubMed
    62. Sánchez-Ortiz RF, Madsen LT, Bermejo CE, Wen S, Shen Y, Swanson DA, Wood CG. A renal mass in the setting of a nonrenal malignancy: When is a renal tumor biopsy appropriate? Cancer. 2004 Nov 15; 101(10):2195-201. PMID: 15470708.
      View in: PubMed
    63. Siefker-Radtke AO, Dinney CP, Abrahams NA, Moran C, Shen Y, Pisters LL, Grossman HB, Swanson DA, Millikan RE. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol. 2004 Aug; 172(2):481-4. PMID: 15247709.
      View in: PubMed
    64. Hu Q, Dey AL, Yang Y, Shen Y, Jilani IB, Estey EH, Kantarjian HM, Giles FJ, Albitar M. Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes. Cancer. 2004 May 01; 100(9):1884-91. PMID: 15112269.
      View in: PubMed
    65. Tsao AS, Kantarjian H, Thomas D, Giles F, Cortes J, Garcia-Manero G, Huh Y, Yang Y, Shen Y, Albitar M, Estey E. C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome. Leuk Res. 2004 Apr; 28(4):373-8. PMID: 15109537.
      View in: PubMed
    66. Kamat AM, Karashima T, Davis DW, Lashinger L, Bar-Eli M, Millikan R, Shen Y, Dinney CP, McConkey DJ. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther. 2004 Mar; 3(3):279-90. PMID: 15026548.
      View in: PubMed
    67. Slaton JW, Millikan R, Inoue K, Karashima T, Czerniak B, Shen Y, Yang Y, Benedict WF, Dinney CP. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol. 2004 Feb; 171(2 Pt 1):570-4. PMID: 14713761.
      View in: PubMed
    68. Siefker-Radtke AO, Walsh GL, Pisters LL, Shen Y, Swanson DA, Logothetis CJ, Millikan RE. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol. 2004 Jan; 171(1):145-8. PMID: 14665863.
      View in: PubMed
    69. Davis DW, Shen Y, Mullani NA, Wen S, Herbst RS, O'Reilly M, Abbruzzese JL, McConkey DJ. Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 1):33-42. PMID: 14734449.
      View in: PubMed
    70. Suzuki S, Kondo Y, Hirashima N, Kato H, Sugauchi F, Tanaka Y, Orito E, Yang Y, Shen Y, Sakakibara K, Ueda R, Mizokami M. Evaluation of loss of heterozygosity before and after interferon therapy in patients with hepatitis C virus infection who developed hepatocellular carcinoma during follow up. J Gastroenterol Hepatol. 2003 Dec; 18(12):1364-72. PMID: 14675264.
      View in: PubMed
    71. Hock BD, McKenzie JL, Patton WN, Haring LF, Yang Y, Shen Y, Estey EH, Albitar M. The clinical significance of soluble CD86 levels in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer. 2003 Oct 15; 98(8):1681-8. PMID: 14534885.
      View in: PubMed
    72. Matin SF, Abreu S, Ramani A, Steinberg AP, Desai M, Strzempkowski B, Yang Y, Shen Y, Gill IS. Evaluation of age and comorbidity as risk factors after laparoscopic urological surgery. J Urol. 2003 Oct; 170(4 Pt 1):1115-20. PMID: 14501704.
      View in: PubMed
    73. Thomas MB, Koller C, Yang Y, Shen Y, O'Brien S, Kantarjian H, Davis J, Estey E. Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia. Leukemia. 2003 May; 17(5):990-3. PMID: 12750721.
      View in: PubMed
    74. Siefker-Radtke AO, Gee J, Shen Y, Wen S, Daliani D, Millikan RE, Pisters LL. Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. J Urol. 2003 Apr; 169(4):1295-8. PMID: 12629346.
      View in: PubMed
    75. Mattiuzzi GN, Estey E, Raad I, Giles F, Cortes J, Shen Y, Kontoyiannis D, Koller C, Munsell M, Beran M, Kantarjian H. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer. 2003 Jan 15; 97(2):450-6. PMID: 12518369.
      View in: PubMed
    76. Albitar M, Manshouri T, Shen Y, Liu D, Beran M, Kantarjian HM, Rogers A, Jilani I, Lin CW, Pierce S, Freireich EJ, Estey EH. Myelodysplastic syndrome is not merely "preleukemia". Blood. 2002 Aug 01; 100(3):791-8. PMID: 12130488.
      View in: PubMed
    77. Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, Wakabayashi N, Shen Y, Zimmerman S, Godio L, Rodrigues-Bigas M, Su LK, Sherman J, Kelloff G, Levin B, Steinbach G. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut. 2002 Jun; 50(6):857-60. PMID: 12010890.
      View in: PubMed
    78. Shen L, Ahuja N, Shen Y, Habib NA, Toyota M, Rashid A, Issa JP. DNA methylation and environmental exposures in human hepatocellular carcinoma. J Natl Cancer Inst. 2002 May 15; 94(10):755-61. PMID: 12011226.
      View in: PubMed
    79. Jeha S, Smith FO, Estey E, Shen Y, Liu D, Manshouri T, Albitar M. Comparison between pediatric acute myeloid leukemia (AML) and adult AML in VEGF and KDR (VEGF-R2) protein levels. Leuk Res. 2002 Apr; 26(4):399-402. PMID: 11839384.
      View in: PubMed
    80. Termuhlen PM, Sweeney-Gotsch BM, Berman RS, Ellis LM, Bucana C, Shen Y, Cleary KR, McConkey DJ. Increased apoptosis in metastatic human colonic adenocarcinomas. Cancer Biol Ther. 2002 Jan-Feb; 1(1):58-63. PMID: 12170764.
      View in: PubMed
    81. Lai R, Estey E, Shen Y, Despa S, Kantarjian H, Beran M, Maushouri T, Quackenbuch RC, Keating M, Albitar M. Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome. Cancer. 2002 Jan 01; 94(1):14-7. PMID: 11815955.
      View in: PubMed
    82. van Haaften-Day C, Shen Y, Xu F, Yu Y, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Bast RC, Hacker NF. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer. 2001 Dec 01; 92(11):2837-44. PMID: 11753957.
      View in: PubMed
    83. Shen Y, Wu D, Zelen M. Testing the independence of two diagnostic tests. Biometrics. 2001 Dec; 57(4):1009-17. PMID: 11764239.
      View in: PubMed
    84. Beran M, Shen Y, Kantarjian H, O'Brien S, Koller CA, Giles FJ, Cortes J, Thomas DA, Faderl S, Despa S, Estey EH. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer. 2001 Oct 15; 92(8):1999-2015. PMID: 11596013.
      View in: PubMed
    85. Shen Y, Cai J. Maximum of the weighted Kaplan-Meier tests with application to cancer prevention and screening trials. Biometrics. 2001 Sep; 57(3):837-43. PMID: 11550935.
      View in: PubMed
    86. Shen Y, Zelen M. Screening sensitivity and sojourn time from breast cancer early detection clinical trials: mammograms and physical examinations. J Clin Oncol. 2001 Aug 01; 19(15):3490-9. PMID: 11481355.
      View in: PubMed
    87. Cortes J, Estey E, O'Brien S, Giles F, Shen Y, Koller C, Beran M, Thomas D, Keating M, Kantarjian H. High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. Cancer. 2001 Jul 01; 92(1):7-14. PMID: 11443603.
      View in: PubMed
    88. Giles FJ, Shen Y, Kantarjian HM, Korbling MJ, O'Brien S, Anderlini P, Donato M, Pierce S, Keating MJ, Freireich EJ, Estey E. Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival. Leuk Lymphoma. 2001 Jun; 42(1-2):67-73. PMID: 11699223.
      View in: PubMed
    89. Cai J, Shen Y. Permutation tests for comparing marginal survival functions with clustered failure time data. Stat Med. 2000 Nov 15; 19(21):2963-73. PMID: 11042626.
      View in: PubMed
    90. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B, Godio L, Patterson S, Rodriguez-Bigas MA, Jester SL, King KL, Schumacher M, Abbruzzese J, DuBois RN, Hittelman WN, Zimmerman S, Sherman JW, Kelloff G. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000 Jun 29; 342(26):1946-52. PMID: 10874062.
      View in: PubMed
    91. Yang LY, Li L, Jiang H, Shen Y, Plunkett W. Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res. 2000 Mar; 6(3):773-81. PMID: 10741696.
      View in: PubMed
    92. Thall PF, Simon RM, Shen Y. Approximate Bayesian evaluation of multiple treatment effects. Biometrics. 2000 Mar; 56(1):213-9. PMID: 10783798.
      View in: PubMed
    93. Estey EH, Shen Y, Thall PF. Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB. Blood. 2000 Jan 01; 95(1):72-7. PMID: 10607687.
      View in: PubMed
    94. Shen Y, Cheng SC. Confidence bands for cumulative incidence curves under the additive risk model. Biometrics. 1999 Dec; 55(4):1093-100. PMID: 11315053.
      View in: PubMed
    95. Sinicrope FA, Lemoine M, Xi L, Lynch PM, Cleary KR, Shen Y, Frazier ML. Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. Gastroenterology. 1999 Aug; 117(2):350-8. PMID: 10419916.
      View in: PubMed
    96. Steinbach G, Ford R, Glober G, Sample D, Hagemeister FB, Lynch PM, McLaughlin PW, Rodriguez MA, Romaguera JE, Sarris AH, Younes A, Luthra R, Manning JT, Johnson CM, Lahoti S, Shen Y, Lee JE, Winn RJ, Genta RM, Graham DY, Cabanillas FF. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med. 1999 Jul 20; 131(2):88-95. PMID: 10419446.
      View in: PubMed
    97. Shen Y, Fisher L. Statistical inference for self-designing clinical trials with a one-sided hypothesis. Biometrics. 1999 Mar; 55(1):190-7. PMID: 11318154.
      View in: PubMed
    98. Shen Y, Fleming TR. Assessing effects on long-term survival after early termination of randomized trials. Lifetime Data Anal. 1999; 5(1):55-66. PMID: 10214002.
      View in: PubMed
    99. Shen Y, Thall PF. Parametric likelihoods for multiple non-fatal competing risks and death. Stat Med. 1998 May 15; 17(9):999-1015. PMID: 9612887.
      View in: PubMed
    100. Sinicrope FA, Roddey G, Lemoine M, Ruan S, Stephens LC, Frazier ML, Shen Y, Zhang W. Loss of p21WAF1/Cip1 protein expression accompanies progression of sporadic colorectal neoplasms but not hereditary nonpolyposis colorectal cancers. Clin Cancer Res. 1998 May; 4(5):1251-61. PMID: 9607584.
      View in: PubMed
    101. Seong D, Thall P, Kantarjian HM, Talpaz M, Swantkowski J, Xu J, Shen Y, Glassman A, Ramagli L, Siciliano MJ. Philadelphia chromosome-positive myeloid cells in the peripheral blood of chronic myelogenous leukemia patients: comparison with the frequency detected in cycling cells of the bone marrow. Clin Cancer Res. 1998 Apr; 4(4):861-7. PMID: 9563879.
      View in: PubMed
    102. Etzioni R, Shen Y. Estimating asymptomatic duration in cancer: the AIDS connection. Stat Med. 1997 Mar 30; 16(6):627-44. PMID: 9131752.
      View in: PubMed
    103. Sinicrope FA, Roddey G, McDonnell TJ, Shen Y, Cleary KR, Stephens LC. Increased apoptosis accompanies neoplastic development in the human colorectum. Clin Cancer Res. 1996 Dec; 2(12):1999-2006. PMID: 9816159.
      View in: PubMed
    104. Midis GP, Shen Y, Owen-Schaub LB. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res. 1996 Sep 01; 56(17):3870-4. PMID: 8752148.
      View in: PubMed
    105. Etzioni R, Shen Y, Petteway JC, Brawer MK. Age-specific prostate-specific antigen: a reassessment. Prostate Suppl. 1996; 7:70-7. PMID: 8950367.
      View in: PubMed
    106. Location of receipt of initial treatment and outcomes in long-term breast cancer survivors. PLoS One. 12.
    107. Large sample properties of some survival estimators in heterogeneous samples. Journal of Statistical Planning and Inference. 60:123-138.
    108. Sample size reestimation for clinical trials with censored survival data. Journal of the American Statistical Association. 98:418-426.
    109. Weighted mean survival test statistics. Journal of the Royal Statistical Society. Series B: Statistical Methodology. 59:269-280.
    110. Breast conserving therapy or mastectomy. Journal of Comparative Effectiveness Research. 4:187-189.
    111. Score Estimating Equations from Embedded Likelihood Functions Under Accelerated Failure Time Model. Journal of the American Statistical Association. 109:1625-1635.
    112. Inference of tamoxifen's effects on prevention of breast cancer from a randomized controlled trial. Journal of the American Statistical Association. 102:1235-1244.
    113. Weighted mean survival test statistics. Journal of the Royal Statistical Society. Series B: Methodological. 59:269-280.
    114. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer. Breast Diseases. 24:95-97.
    115. Sample size calculations for prevalent cohort designs. Statistical Methods in Medical Research. 26:280-291.
    116. Long-term results and pharmacokinetics of high-dose paclitaxel in patients with refractory epithelial ovarian carcinoma. International Journal of Gynecological Cancer. 9:44-53.
    117. Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. British Journal of Cancer.
    118. Evaluation of potassium values in a cancer patient population. Laboratory Medicine. 36:95-97.
    119. Disparities in the Use of Postmastectomy Radiation Therapy for Inflammatory Breast Cancer. International Journal of Radiation Oncology Biology Physics.
    120. Non-parametric tests for right-censored data with biased sampling. Journal of the Royal Statistical Society. Series B: Statistical Methodology. 72:609-630.
    121. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy. European Urology.
    122. Has racial difference in cause-specific death improved in older patients with late-stage breast cancer?. Annals of Oncology. 26:2161-2168.
    123. An efficient sequential design of clinical trials. Journal of Statistical Planning and Inference. 143:283-295.
    124. A semiparametric regression cure model for interval-censored data. Journal of the American Statistical Association. 104:1168-1178.
    125. High her2/centromeric probeforchromosome17fluorescence insitu hybridization ratio predicts pathologic complete response and survival outcomein patients receiving neoadjuvant systemic therapy with trastuzumab for her2-overexpressing locally advanced breast cancer. Oncologist. 21:21-27.
    126. Nonparametric and semiparametric regression estimation for length-biased survival data. Lifetime Data Analysis. 1-22.
    127. A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial. Biometrics. 61.
    128. Semiparametric accelerated failure time model for length-biased data with application to dementia study. Statistica Sinica. 24:313-333.
    129. Erratum. Breast Cancer Research and Treatment. 152:417.
    130. Outcomes of contralateral prophylactic mastectomy in relation to familial history. Breast Cancer Research. 18.
    131. Analyzing length-biased data with semiparametric transformation and accelerated failure time models. Journal of the American Statistical Association. 104:1192-1202.
    132. High dose (hd) chemotherapy in high risk (hr) myelodisplastic syndrome (mds). Blood. 96.
    133. A rapid tumor marker assay detects NMP22 in urine. Cancer Biology and Therapy. 4.
    134. Maximum likelihood estimations and EM algorithms with length-biased data. Journal of the American Statistical Association. 106:1434-1449.
    135. Bayesian adaptive designs for clinical trials. Biometrika. 92:633-646.
    136. Parametric estimation procedures for screening programmes. Biometrika. 86:503-515.
    137. Risk-Specific Optimal Cancer Screening Schedules. Statistics in Biosciences. 3:169-186.
    138. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Research and Treatment.
    139. Semiparametric additive risks model for interval-censored data. Statistica Sinica. 16:287-302.
    140. Likelihood approaches for the invariant density ratio model with biased-sampling data. Biometrika. 99:363-378.
    141. A Phase l Study of a Tumor-targeted Systemic Nanodelivery System, SGT-94, in Genitourinary Cancers. Molecular Therapy.
    SHEN's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (445) concept(s)
    _
    Co-Authors Expand Description
    See all (86) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department